32 results about "Specific lectin" patented technology

The invention discloses a lectin chip for joint detection of ten carbohydrate chains in human serum as well as preparation and use methods of the lectin chip. Ten specific lectin probes are fixed on the surface of a solid-phase carrier in a dot matrix manner, and joint detection of ten carbohydrate chains in human serum is realized by coating ten specific lectins, wherein the solid phase carrier is a gold foil chip chemically modified by 16-amino-1-hexadecanethiol and DOTA-NHS-ester, and three carboxyls at the tail end of DOTA-NHS-ester are activated by EDC and NHS to fix specific lectins as probes. The chip has the advantages of high throughput, high selectivity, high specificity and the like and is more applicable to research of human tumor glycosyl spectrum characteristics.

The invention provides application of a specific lectin composition in preparing a test carrier for identifying epithelial ovarian cancer, and a kit. Aiming at a saliva sample, the specific lectin composition comprises (1) a composition of PSA, SNA, MAL-II, ECA and HHL for a healthy crowd; (2) a composition of PHA-E, LTL and PNA for patients with benign ovarian diseases; (3) a composition of RCA120, UEA-I, ConA, LCA, AAL, WFA, WGA, DBA, VVA, NPA and GNA for patients with epithelial ovarian diseases. Through specific combining of lectin and glycoprotein carbohydrate chain in saliva, glycoprotein and a carbohydrate chain structure in differential expression in the saliva sample of a patient can be quickly detected, and multiple glycoprotein and carbohydrate chain structures in the sample canbe quickly detected in high flux.

The present invention provides a method and a kit for accurately predicting the prognosis (mortality rate) and risk of developing hepatocellular carcinoma in liver cirrhosis patients. The present invention provides: a method by which an 'index for evaluating the risk of developing hepatocellular carcinoma, 'which is used for predicting the prognosis and risk of developing hepatocellular carcinomain liver cirrhosis patients, is calculated as the ratio of CSF1R that contains WFA/VVA-binding sugars relative to the total CSF1R content of bodily fluid (blood serum) (WFA+-CSF1R%); and a method by which a 'prognosis evaluation index ' is calculated as the amount of CSF1R that contains WFA/VVA-binding sugars (WFA+-CSF1R ng/mL). Furthermore, an optimal cutoff value was determined for each of the indices, and it was proven that: the risk of developing hepatocellular carcinoma was significantly high when the 'index for evaluating the risk of developing hepatocellular carcinoma ' in a subject wasequal to or greater than the optimal cutoff value; and the prognosis was significantly poor when the 'prognosis evaluation index ' was equal to or greater than the optimal cutoff value. In addition,anti-CSF1R antibodies (CSR-1-30), which are exceptional for detecting CSF1Rs such as CSF1Rs that contain WFA/VVA-binding sugars in a bodily fluid sample, were provided. It was discovered that srWFA and VVA lectins other than WFA lectins can be used, and it was additionally proven that measuring the amount of CSF1R that binds to a CSF1R-specific lectin is preferable to measuring the total amount ofCSF1R. It was also possible to provide, inter alia, a kit for measuring the 'prognosis evaluation index ' and/or 'index for evaluating the risk of developing hepatocellular carcinoma ' in a liver cirrhosis patient, the kit including these anti-CSF1R antibodies and lectins as constituent elements.

The invention provides an application of specific lectin combination in construction of a test tool for identifying lung diseases based on saliva glycoprotein carbohydrate chains, wherein the specificlectin combination is selected from seven lectins, namely, PHA-E+L, PWM, ConA, RCA120, SJA, PTL-I and Jacalin. Compared with a healthy sample, lung disease samples show significantly different expression of the specific lectin combination; a model PUD is established and shown in the specification; if the detection value is greater than or equal to 0.913, it is indicated that a subject to which the saliva sample belongs is a lung disease patient, or otherwise, the subject to which the saliva sample belongs is a healthy person.

The invention provides an application of a specific lectin combination in identifying an esophageal cancer based on saliva sugar types. The specific lectin combination (identified sugar chain) servesas a biomarker for identifying an esophageal cancer based on saliva sugar types and comprises an up-regulation group and a down-regulation group. The up-regulation group comprises Jacalin, ECA, HHL, GSL-II, MAL-II, EEL, RCA120, DSA, NPA, and MAL-I. The down-regulation group comprises SJA, LEL, LCA, STL, ConA, PSA, ACA, PWM, and GNA. When all the sugar chains identified by each lectin of the up-regulation group are up-regulated, and all the sugar chains identified by each lectin of the down-regulation group are down-regulated, the corresponding individual is indicated to have an esophageal cancer. According to the application of a specific lectin combination in identifying an esophageal cancer based on saliva sugar types, the non-injury, high throughput, and rapid identification of an esophageal cancer can be realized.

The invention belongs to the technical field of microbiological detection, and discloses an influenza hemagglutination inhibition test detection method which comprises the following steps: pretreatingstandard reference antiserum to remove non-specific inhibin and non-specific lectin in the serum; preparing an erythrocyte suspension; determining the hemagglutination titer of the influenza virus strain; preparing four hemagglutination unit antigens for an erythrocyte agglutination inhibition test; rechecking and titrating four hemagglutination unit antigens; and performing influenza virus identification and antigen analysis by using an HAI method to obtain the serum titer of the detected serum. According to the detection method, chicken erythrocyte, turkey erythrocyte and guinea pig erythrocyte are used as raw materials to prepare erythrocyte suspension, animal erythrocyte is used for replacing human erythrocyte, and the difficulty that an experiment cannot be conducted due to lack of erythrocyte is solved.

The invention discloses an application of a specific lectin combination in construction of a test tool for identifying ultra-early liver cancer based on a saliva glycoprotein sugar chain, wherein thespecific lectin combination is selected from three kinds of lectin of LTL, STL and MAL-I; compared with a liver cirrhosis sample, an ultra-early liver cancer sample has the advantages that LTL and MAL-I are significantly up-regulated, and STL is significantly down-regulated. Besides, an accurate test model is constructed, and a user can calculate the following detection values according to a lectin test result; if the detection value is greater than or equal to 0.4931, it is indicated that the main body to which the saliva sample belongs is an ultra-early liver cancer patient (UE-HCC), otherwise, it is indicated that the main body to which the saliva sample belongs is a liver cirrhosis patient (HC).

The invention discloses an application of a specific lectin combination in constructing a test tool for identifying liver fibrosis (HF) based on a saliva glycoprotein sugar chain. The specific lectincombination is selected from the group consisting of lectin RCA120, PHEE-E + L, EEL, AAL and DSA; compared with a hepatitis B sample, the liver fibrosis sample has the advantages that RCA120, PHE-E +L and EEL are remarkably reduced, and AAL and DSA are remarkably increased. Besides, an accurate test model is also constructed: if the detection value is greater than or equal to 0.1701, the main body to which the saliva sample belongs is indicated to be a liver fibrosis patient (HF), otherwise, if the detection value is smaller than 0.1701, the main body to which the saliva sample belongs is indicated to be a hepatitis B patient (HB).

The invention discloses application of specific lectin in identification of pancreatic cancer based on a saliva glycoprotein sugar chain structure and a related product. The specific lectin is dividedinto an up-regulation group and a down-regulation group; the upper regulation group is any one or any combination of lectin ECA, PHA-E, GSL-I, LCA, RCA120, ACA, MAL-I and PHA-E + L, and the lower regulation group is any one or any combination of lectin Jacalin, MAL-II, SJA, MPL, PTL-II, DSA, PWM and SNA; the identification basis is as follows: for a detected saliva sample, if the expression of the glycoprotein carbohydrate chain structure identified by the up-regulation group is significantly up-regulated and the expression of the glycoprotein carbohydrate chain structure identified by the down-regulation group is significantly down-regulated, the corresponding subject is indicated to be a pancreatic cancer patient.

The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.

The invention provides application of specific lectin in identifying diabetic/non-diabetic nephropathy based on saliva glycoprotein sugar chains. The specific lectin is divided into an up-regulation group and a down-regulation group; the up-regulation group is at least one of NPA, HHL, PHA-E+L and PTL-II; the down-regulation group is at least one of MPL, SBA, LTL and AAL; if glycoprotein sugar chain structure expressions recognized by the up-regulation group and the down-regulation group are respectively and remarkably up-regulated and remarkably down-regulated, it is indicated that the nephropathy is particularly diabetic nephropathy (DN); otherwise, it is determined that the disease is non-diabetic nephropathy (NDRD); in addition, the following detection models are also constructed: if the detection value is less than or equal to 0.443, diabetic nephropathy is determined; otherwise, if the detection value is greater than 0.443, the patient is non-diabetic nephropathy.

The invention provides an application of specific lectin in preparation of a test tool for identifying lung cancer and a device. For a sample taken from bronchoalveolar lavage fluid, the specific lectin is any one or any combination of the following lectins: MAL-II, RCA120, ECA, HHL, GSL-I, DBA, DSA and AAL. When a sugar chain structure identified by the lectins MAL-II, RCA 120, ECA, and HHL is significantly increased and a sugar chain structure identified by the lectins GSL-I, DBA, DSA, and AAL is significantly reduced, the sample comes from a patient with benign pulmonary disease (BPD), otherwise the sample comes from a lung cancer patient as determined. According to the invention, the bronchoalveolar lavage fluid is used as a test sample. Since the sample is directly obtained from a primary lesion adjacent to tumor cells, it has high organ specificity and can directly reflect true condition of the patient. The test tool of the invention is safe and minimally invasive.

The invention provides an application of specific lectin combination in construction of a test tool for identifying adenocarcinoma (ADC) in lung cancer based on saliva glycoprotein carbohydrate chains, wherein the specific lectin combination is selected from four kinds of lectin of PHA-E+L, STL, WFA and Jacalin. Compared with lung squamous cell carcinoma (SCC) and small cell lung cancer (SCLC) samples, an adenocarcinoma (ADC) sample shows significantly different expression of the specific lectin combination. Moreover, a model is also established and shown in the specification; if the detectionvalue is greater than or equal to 0.697, it is indicated that the subject to which a saliva sample belongs to is an ADC patient, or otherwise, the subject to which the saliva sample belongs is otherlung disease patients (SCC, SCLC or COPD patients).

[Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test.

[Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose α1→6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×10⁴ M⁻¹ or more (at 25° C.) for an α1→6 fucose sugar chain No. 405. The fucose α1→6 affinitive lectin is preferably (2) a fucose α1→6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×10⁴ M⁻¹ or less (at 25° C.) for a sugar chain No. 003 that does not contain α1→6 fucose and a glycolipid-type sugar chain No. 909 that does not contain α1→6 fucose.

The invention belongs to the field of biomedical detection, and relates to application of a specific lectin combination combined with IgG and/or IgM in serum and alpha fetoprotein (AFP) to construction of a test tool for identifying liver cancer. By utilizing a lectin chip technology, lectin which is combined with IgG (12 types)/IgM (11 types) is screened out, and differences exist between liver cancer and healthy people, and hepatitis B and hepatitis B cirrhosis patients. A test tool for identifying the liver cancer is jointly constructed based on a specific lectin combination combined with IgG/IgM in serum and AFP, a liver cancer identification combined diagnosis model is established in combination with an algorithm, the test tool can identify and diagnose the liver cancer and distinguish the liver cancer from hepatitis B cirrhosis and chronic hepatitis B diseases, and meanwhile, for AFP negative patients, the test tool can be used for identifying and diagnosing the liver cancer. The method can be used as a powerful supplement for in-vitro diagnosis.

The invention discloses an SPDP modified lectin chip for detecting liver cancer serum carbohydrate chains as well as preparation and application of the SPDP modified lectin chip. A gold foil chip chemically modified by SPDP is used as a solid-phase carrier, fifteen specific lectin probes are fixed on the surface of the gold foil chip in a dot matrix mode, and joint detection of at least fifteen carbohydrate chains in human serum is achieved by coating fifteen specific lectin. The lectin chip provided by the invention can accurately detect at least fifteen carbohydrate chains in serum of a liver cancer patient, has the advantages of high flux, high selectivity, high specificity and the like, and is more suitable for research of human tumor glycosyl spectrum characteristics.

The invention provides an application of specific lectin combination in construction of a test tool for identifying small-cell lung cancer (SCLC) based on saliva glycoprotein carbohydrate chains, wherein the specific lectin combination is selected from two lectins of WGA and HHL. Compared with lung adenocarcinoma (ADC) and squamous-cell carcinoma (SCC) samples, small-cell lung cancer (SCLC) samples show significantly different expression of the specific lectin combination. Moreover, a model is established and shown in the specification; and if the detection value is less than or equal to 0.784, it is indicated that a subject to which the saliva sample belongs is an SCLC patient, or otherwise, if the detection value is larger than 0.784, it is indicated that the subject to which the salivasample belongs is other lung disease patients (ADC, SCC or COPD patients).

The invention provides a use of specific lectin in the preparation of test tools for verifying lung cancer types, and a device. In view of a sample taken from bronchoalveolar lavage fluid, the specific lectin can be divided into two groups: the group A contains PHA-E, EEL, BPL, GSL-II, VVA and PNA for judging whether the sample is from a patient with adenocarcinoma of lung; the group B contains PNA and MPL for judging whether the sample is from a patient with squamous cell lung carcinoma; and if it is known in advance that the subject is a patient with lung cancer, whether the sample is from apatient with small cell lung cancer can be deduced according to the test results of the group A and the group B. According to the use provided by the invention, the bronchoalveolar lavage fluid is used as an object to be detected, since the object to be detected is a sample obtained directly from the primary lesion and adjacent tumor cells, the object to be detected has high organ specificity, can directly reflect the true state of the body of the patient, and is safe and minimally invasive.